nodes	percent_of_prediction	percent_of_DWPC	metapath
Adenosine—Fludarabine—lymphatic system cancer	0.235	0.514	CrCtD
Adenosine—Cytarabine—lymphatic system cancer	0.222	0.486	CrCtD
Adenosine—SLC28A3—Fludarabine—lymphatic system cancer	0.207	1	CbGbCtD
Adenosine—Glucosamine—Cytarabine—lymphatic system cancer	0.0226	0.0716	CrCrCtD
Adenosine—Adenosine triphosphate—Fludarabine—lymphatic system cancer	0.018	0.057	CrCrCtD
Adenosine—Ribavirin—Fludarabine—lymphatic system cancer	0.0167	0.0528	CrCrCtD
Adenosine—Ribavirin—Cytarabine—lymphatic system cancer	0.0157	0.0499	CrCrCtD
Adenosine—Regadenoson—Fludarabine—lymphatic system cancer	0.0155	0.0493	CrCrCtD
Adenosine—S-Adenosylmethionine—Fludarabine—lymphatic system cancer	0.0155	0.0493	CrCrCtD
Adenosine—Clofarabine—Fludarabine—lymphatic system cancer	0.0155	0.0493	CrCrCtD
Adenosine—Clofarabine—Cytarabine—lymphatic system cancer	0.0147	0.0466	CrCrCtD
Adenosine—S-Adenosylmethionine—Cytarabine—lymphatic system cancer	0.0147	0.0466	CrCrCtD
Adenosine—Regadenoson—Cytarabine—lymphatic system cancer	0.0147	0.0466	CrCrCtD
Adenosine—Fludarabine—Cytarabine—lymphatic system cancer	0.0138	0.0437	CrCrCtD
Adenosine—Nelarabine—Fludarabine—lymphatic system cancer	0.0137	0.0436	CrCrCtD
Adenosine—Adenosine monophosphate—Fludarabine—lymphatic system cancer	0.0137	0.0436	CrCrCtD
Adenosine—Cytarabine—Fludarabine—lymphatic system cancer	0.013	0.0412	CrCrCtD
Adenosine—Nelarabine—Cytarabine—lymphatic system cancer	0.013	0.0412	CrCrCtD
Adenosine—Adenosine monophosphate—Cytarabine—lymphatic system cancer	0.013	0.0412	CrCrCtD
Adenosine—Cladribine—Fludarabine—lymphatic system cancer	0.0123	0.0392	CrCrCtD
Adenosine—Vidarabine—Fludarabine—lymphatic system cancer	0.0123	0.0392	CrCrCtD
Adenosine—Azacitidine—Fludarabine—lymphatic system cancer	0.0123	0.0392	CrCrCtD
Adenosine—Vidarabine—Cytarabine—lymphatic system cancer	0.0117	0.037	CrCrCtD
Adenosine—Azacitidine—Cytarabine—lymphatic system cancer	0.0117	0.037	CrCrCtD
Adenosine—Decitabine—Cytarabine—lymphatic system cancer	0.0111	0.0352	CrCrCtD
Adenosine—Adenosine triphosphate—ALK—lymphatic system cancer	0.00083	1	CrCbGaD
Adenosine—Tonic-clonic seizures—Carmustine—lymphatic system cancer	0.000728	0.0359	CcSEcCtD
Adenosine—Coronary artery disease—Vincristine—lymphatic system cancer	0.000474	0.0233	CcSEcCtD
Adenosine—Intracranial pressure increased—Carmustine—lymphatic system cancer	0.000469	0.0231	CcSEcCtD
Adenosine—Haemorrhage intracranial—Mitoxantrone—lymphatic system cancer	0.000444	0.0219	CcSEcCtD
Adenosine—Grand mal convulsion—Carmustine—lymphatic system cancer	0.000412	0.0203	CcSEcCtD
Adenosine—Numbness—Fludarabine—lymphatic system cancer	0.00037	0.0182	CcSEcCtD
Adenosine—Sensory loss—Fludarabine—lymphatic system cancer	0.000354	0.0174	CcSEcCtD
Adenosine—Respiratory failure—Fludarabine—lymphatic system cancer	0.000312	0.0154	CcSEcCtD
Adenosine—Taste metallic—Methotrexate—lymphatic system cancer	0.000286	0.0141	CcSEcCtD
Adenosine—Burning sensation—Carmustine—lymphatic system cancer	0.000282	0.0139	CcSEcCtD
Adenosine—Scotoma—Carmustine—lymphatic system cancer	0.000258	0.0127	CcSEcCtD
Adenosine—Cardiac failure—Fludarabine—lymphatic system cancer	0.000228	0.0112	CcSEcCtD
Adenosine—Cerebrovascular accident—Fludarabine—lymphatic system cancer	0.000227	0.0112	CcSEcCtD
Adenosine—Myocardial ischaemia—Mitoxantrone—lymphatic system cancer	0.000227	0.0112	CcSEcCtD
Adenosine—Numbness—Vincristine—lymphatic system cancer	0.000226	0.0111	CcSEcCtD
Adenosine—Tinnitus—Mechlorethamine—lymphatic system cancer	0.000221	0.0109	CcSEcCtD
Adenosine—Sensory loss—Vincristine—lymphatic system cancer	0.000216	0.0107	CcSEcCtD
Adenosine—Bronchospasm—Teniposide—lymphatic system cancer	0.000215	0.0106	CcSEcCtD
Adenosine—Injection site reaction—Carmustine—lymphatic system cancer	0.000195	0.00961	CcSEcCtD
Adenosine—Respiratory failure—Vincristine—lymphatic system cancer	0.000191	0.0094	CcSEcCtD
Adenosine—Sweating—Teniposide—lymphatic system cancer	0.000187	0.00922	CcSEcCtD
Adenosine—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.000169	0.00833	CcSEcCtD
Adenosine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.000169	0.00832	CcSEcCtD
Adenosine—Myocardial infarction—Fludarabine—lymphatic system cancer	0.000168	0.00828	CcSEcCtD
Adenosine—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.000166	0.0082	CcSEcCtD
Adenosine—Flushing—Teniposide—lymphatic system cancer	0.000162	0.00801	CcSEcCtD
Adenosine—Arrhythmia—Teniposide—lymphatic system cancer	0.000156	0.00771	CcSEcCtD
Adenosine—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.000153	0.00755	CcSEcCtD
Adenosine—Agitation—Teniposide—lymphatic system cancer	0.00014	0.0069	CcSEcCtD
Adenosine—Bronchospasm—Bleomycin—lymphatic system cancer	0.000139	0.00683	CcSEcCtD
Adenosine—Arrhythmia—Fludarabine—lymphatic system cancer	0.000137	0.00678	CcSEcCtD
Adenosine—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.000136	0.00668	CcSEcCtD
Adenosine—Hypertension—Teniposide—lymphatic system cancer	0.000132	0.00649	CcSEcCtD
Adenosine—Burning sensation—Methotrexate—lymphatic system cancer	0.000131	0.00645	CcSEcCtD
Adenosine—Chest pain—Teniposide—lymphatic system cancer	0.00013	0.0064	CcSEcCtD
Adenosine—Cardiac arrest—Vincristine—lymphatic system cancer	0.000129	0.00637	CcSEcCtD
Adenosine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000124	0.00613	CcSEcCtD
Adenosine—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.000124	0.00611	CcSEcCtD
Adenosine—Myocardial infarction—Bleomycin—lymphatic system cancer	0.000123	0.00607	CcSEcCtD
Adenosine—Agitation—Fludarabine—lymphatic system cancer	0.000123	0.00607	CcSEcCtD
Adenosine—Tachycardia—Teniposide—lymphatic system cancer	0.000121	0.00598	CcSEcCtD
Adenosine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00012	0.00593	CcSEcCtD
Adenosine—Cough—Fludarabine—lymphatic system cancer	0.000117	0.00576	CcSEcCtD
Adenosine—Hypotension—Teniposide—lymphatic system cancer	0.000116	0.00573	CcSEcCtD
Adenosine—Convulsion—Fludarabine—lymphatic system cancer	0.000116	0.00572	CcSEcCtD
Adenosine—Discomfort—Fludarabine—lymphatic system cancer	0.000113	0.00555	CcSEcCtD
Adenosine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.000112	0.00553	CcSEcCtD
Adenosine—Dyspnoea—Teniposide—lymphatic system cancer	0.000111	0.00547	CcSEcCtD
Adenosine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000109	0.00539	CcSEcCtD
Adenosine—Vomiting—Mechlorethamine—lymphatic system cancer	0.000107	0.00529	CcSEcCtD
Adenosine—Apnoea—Methotrexate—lymphatic system cancer	0.000107	0.00528	CcSEcCtD
Adenosine—Rash—Mechlorethamine—lymphatic system cancer	0.000106	0.00524	CcSEcCtD
Adenosine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000106	0.00524	CcSEcCtD
Adenosine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000106	0.00521	CcSEcCtD
Adenosine—Flushing—Bleomycin—lymphatic system cancer	0.000105	0.00516	CcSEcCtD
Adenosine—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000103	0.00509	CcSEcCtD
Adenosine—Myocardial infarction—Vincristine—lymphatic system cancer	0.000103	0.00506	CcSEcCtD
Adenosine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000102	0.00503	CcSEcCtD
Adenosine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000101	0.00496	CcSEcCtD
Adenosine—Sweating—Vincristine—lymphatic system cancer	0.0001	0.00495	CcSEcCtD
Adenosine—Nausea—Mechlorethamine—lymphatic system cancer	0.0001	0.00494	CcSEcCtD
Adenosine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.0001	0.00493	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	9.96e-05	0.00491	CcSEcCtD
Adenosine—Urticaria—Teniposide—lymphatic system cancer	9.88e-05	0.00487	CcSEcCtD
Adenosine—Paraesthesia—Fludarabine—lymphatic system cancer	9.82e-05	0.00484	CcSEcCtD
Adenosine—Hypoaesthesia—Carmustine—lymphatic system cancer	9.8e-05	0.00483	CcSEcCtD
Adenosine—Sweating—Mitoxantrone—lymphatic system cancer	9.78e-05	0.00482	CcSEcCtD
Adenosine—Dyspnoea—Fludarabine—lymphatic system cancer	9.75e-05	0.0048	CcSEcCtD
Adenosine—Hypoaesthesia—Vincristine—lymphatic system cancer	9.35e-05	0.00461	CcSEcCtD
Adenosine—Pain—Fludarabine—lymphatic system cancer	9.35e-05	0.00461	CcSEcCtD
Adenosine—Bradycardia—Mitoxantrone—lymphatic system cancer	9.32e-05	0.00459	CcSEcCtD
Adenosine—Respiratory failure—Methotrexate—lymphatic system cancer	9.25e-05	0.00456	CcSEcCtD
Adenosine—Hypersensitivity—Teniposide—lymphatic system cancer	9.16e-05	0.00452	CcSEcCtD
Adenosine—Flushing—Carmustine—lymphatic system cancer	9.14e-05	0.00451	CcSEcCtD
Adenosine—Asthenia—Teniposide—lymphatic system cancer	8.92e-05	0.0044	CcSEcCtD
Adenosine—Arrhythmia—Carmustine—lymphatic system cancer	8.8e-05	0.00434	CcSEcCtD
Adenosine—Cardiac disorder—Vincristine—lymphatic system cancer	8.72e-05	0.0043	CcSEcCtD
Adenosine—Cough—Bleomycin—lymphatic system cancer	8.57e-05	0.00422	CcSEcCtD
Adenosine—Mediastinal disorder—Vincristine—lymphatic system cancer	8.47e-05	0.00418	CcSEcCtD
Adenosine—Chest pain—Bleomycin—lymphatic system cancer	8.36e-05	0.00412	CcSEcCtD
Adenosine—Back pain—Carmustine—lymphatic system cancer	8.29e-05	0.00409	CcSEcCtD
Adenosine—Discomfort—Bleomycin—lymphatic system cancer	8.26e-05	0.00407	CcSEcCtD
Adenosine—Arrhythmia—Mitoxantrone—lymphatic system cancer	8.18e-05	0.00403	CcSEcCtD
Adenosine—Vision blurred—Carmustine—lymphatic system cancer	8.08e-05	0.00398	CcSEcCtD
Adenosine—Hypersensitivity—Fludarabine—lymphatic system cancer	8.05e-05	0.00397	CcSEcCtD
Adenosine—Tremor—Carmustine—lymphatic system cancer	8.03e-05	0.00396	CcSEcCtD
Adenosine—Anaphylactic shock—Bleomycin—lymphatic system cancer	8.01e-05	0.00395	CcSEcCtD
Adenosine—Back pain—Vincristine—lymphatic system cancer	7.92e-05	0.0039	CcSEcCtD
Adenosine—Vomiting—Teniposide—lymphatic system cancer	7.91e-05	0.0039	CcSEcCtD
Adenosine—Agitation—Carmustine—lymphatic system cancer	7.88e-05	0.00388	CcSEcCtD
Adenosine—Asthenia—Fludarabine—lymphatic system cancer	7.84e-05	0.00387	CcSEcCtD
Adenosine—Rash—Teniposide—lymphatic system cancer	7.84e-05	0.00387	CcSEcCtD
Adenosine—Dermatitis—Teniposide—lymphatic system cancer	7.83e-05	0.00386	CcSEcCtD
Adenosine—Dysgeusia—Mitoxantrone—lymphatic system cancer	7.8e-05	0.00385	CcSEcCtD
Adenosine—Headache—Teniposide—lymphatic system cancer	7.79e-05	0.00384	CcSEcCtD
Adenosine—Back pain—Mitoxantrone—lymphatic system cancer	7.71e-05	0.0038	CcSEcCtD
Adenosine—Agitation—Vincristine—lymphatic system cancer	7.52e-05	0.00371	CcSEcCtD
Adenosine—Vision blurred—Mitoxantrone—lymphatic system cancer	7.51e-05	0.0037	CcSEcCtD
Adenosine—Hypotension—Bleomycin—lymphatic system cancer	7.49e-05	0.00369	CcSEcCtD
Adenosine—Convulsion—Carmustine—lymphatic system cancer	7.43e-05	0.00366	CcSEcCtD
Adenosine—Hypertension—Carmustine—lymphatic system cancer	7.4e-05	0.00365	CcSEcCtD
Adenosine—Nausea—Teniposide—lymphatic system cancer	7.39e-05	0.00364	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	7.3e-05	0.0036	CcSEcCtD
Adenosine—Chest pain—Carmustine—lymphatic system cancer	7.3e-05	0.0036	CcSEcCtD
Adenosine—Anxiety—Carmustine—lymphatic system cancer	7.27e-05	0.00359	CcSEcCtD
Adenosine—Paraesthesia—Bleomycin—lymphatic system cancer	7.2e-05	0.00355	CcSEcCtD
Adenosine—Dyspnoea—Bleomycin—lymphatic system cancer	7.15e-05	0.00352	CcSEcCtD
Adenosine—Convulsion—Vincristine—lymphatic system cancer	7.09e-05	0.0035	CcSEcCtD
Adenosine—Hypertension—Vincristine—lymphatic system cancer	7.06e-05	0.00348	CcSEcCtD
Adenosine—Cough—Mitoxantrone—lymphatic system cancer	6.95e-05	0.00343	CcSEcCtD
Adenosine—Vomiting—Fludarabine—lymphatic system cancer	6.95e-05	0.00343	CcSEcCtD
Adenosine—Convulsion—Mitoxantrone—lymphatic system cancer	6.9e-05	0.0034	CcSEcCtD
Adenosine—Rash—Fludarabine—lymphatic system cancer	6.89e-05	0.0034	CcSEcCtD
Adenosine—Dermatitis—Fludarabine—lymphatic system cancer	6.89e-05	0.00339	CcSEcCtD
Adenosine—Hypertension—Mitoxantrone—lymphatic system cancer	6.88e-05	0.00339	CcSEcCtD
Adenosine—Pain—Bleomycin—lymphatic system cancer	6.85e-05	0.00338	CcSEcCtD
Adenosine—Headache—Fludarabine—lymphatic system cancer	6.85e-05	0.00338	CcSEcCtD
Adenosine—Tachycardia—Carmustine—lymphatic system cancer	6.83e-05	0.00337	CcSEcCtD
Adenosine—Chest pain—Mitoxantrone—lymphatic system cancer	6.78e-05	0.00334	CcSEcCtD
Adenosine—Anxiety—Mitoxantrone—lymphatic system cancer	6.76e-05	0.00333	CcSEcCtD
Adenosine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	6.73e-05	0.00332	CcSEcCtD
Adenosine—Discomfort—Mitoxantrone—lymphatic system cancer	6.7e-05	0.0033	CcSEcCtD
Adenosine—Anaphylactic shock—Vincristine—lymphatic system cancer	6.68e-05	0.00329	CcSEcCtD
Adenosine—Hypotension—Carmustine—lymphatic system cancer	6.54e-05	0.00322	CcSEcCtD
Adenosine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	6.5e-05	0.00321	CcSEcCtD
Adenosine—Nausea—Fludarabine—lymphatic system cancer	6.49e-05	0.0032	CcSEcCtD
Adenosine—Hyperhidrosis—Vincristine—lymphatic system cancer	6.46e-05	0.00318	CcSEcCtD
Adenosine—Shock—Mitoxantrone—lymphatic system cancer	6.4e-05	0.00315	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	6.37e-05	0.00314	CcSEcCtD
Adenosine—Urticaria—Bleomycin—lymphatic system cancer	6.37e-05	0.00314	CcSEcCtD
Adenosine—Tachycardia—Mitoxantrone—lymphatic system cancer	6.35e-05	0.00313	CcSEcCtD
Adenosine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	6.29e-05	0.0031	CcSEcCtD
Adenosine—Paraesthesia—Carmustine—lymphatic system cancer	6.28e-05	0.0031	CcSEcCtD
Adenosine—Mood swings—Methotrexate—lymphatic system cancer	6.25e-05	0.00308	CcSEcCtD
Adenosine—Hypotension—Vincristine—lymphatic system cancer	6.24e-05	0.00308	CcSEcCtD
Adenosine—Dyspnoea—Carmustine—lymphatic system cancer	6.24e-05	0.00307	CcSEcCtD
Adenosine—Somnolence—Carmustine—lymphatic system cancer	6.22e-05	0.00307	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	6.08e-05	0.003	CcSEcCtD
Adenosine—Hypotension—Mitoxantrone—lymphatic system cancer	6.08e-05	0.003	CcSEcCtD
Adenosine—Paraesthesia—Vincristine—lymphatic system cancer	6e-05	0.00296	CcSEcCtD
Adenosine—Pain—Carmustine—lymphatic system cancer	5.98e-05	0.00295	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	5.93e-05	0.00292	CcSEcCtD
Adenosine—Hypersensitivity—Bleomycin—lymphatic system cancer	5.9e-05	0.00291	CcSEcCtD
Adenosine—Paraesthesia—Mitoxantrone—lymphatic system cancer	5.84e-05	0.00288	CcSEcCtD
Adenosine—Dyspnoea—Mitoxantrone—lymphatic system cancer	5.8e-05	0.00286	CcSEcCtD
Adenosine—Somnolence—Mitoxantrone—lymphatic system cancer	5.78e-05	0.00285	CcSEcCtD
Adenosine—Asthenia—Bleomycin—lymphatic system cancer	5.75e-05	0.00283	CcSEcCtD
Adenosine—Pain—Vincristine—lymphatic system cancer	5.71e-05	0.00282	CcSEcCtD
Adenosine—Pain—Mitoxantrone—lymphatic system cancer	5.56e-05	0.00274	CcSEcCtD
Adenosine—Abdominal discomfort—Methotrexate—lymphatic system cancer	5.46e-05	0.00269	CcSEcCtD
Adenosine—Urticaria—Mitoxantrone—lymphatic system cancer	5.17e-05	0.00255	CcSEcCtD
Adenosine—Hypersensitivity—Carmustine—lymphatic system cancer	5.15e-05	0.00254	CcSEcCtD
Adenosine—Vomiting—Bleomycin—lymphatic system cancer	5.1e-05	0.00251	CcSEcCtD
Adenosine—Drowsiness—Methotrexate—lymphatic system cancer	5.08e-05	0.0025	CcSEcCtD
Adenosine—Rash—Bleomycin—lymphatic system cancer	5.05e-05	0.00249	CcSEcCtD
Adenosine—Dermatitis—Bleomycin—lymphatic system cancer	5.05e-05	0.00249	CcSEcCtD
Adenosine—Asthenia—Carmustine—lymphatic system cancer	5.02e-05	0.00247	CcSEcCtD
Adenosine—Hypersensitivity—Vincristine—lymphatic system cancer	4.92e-05	0.00243	CcSEcCtD
Adenosine—Sweating—Methotrexate—lymphatic system cancer	4.87e-05	0.0024	CcSEcCtD
Adenosine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	4.79e-05	0.00236	CcSEcCtD
Adenosine—Asthenia—Vincristine—lymphatic system cancer	4.79e-05	0.00236	CcSEcCtD
Adenosine—Nausea—Bleomycin—lymphatic system cancer	4.76e-05	0.00235	CcSEcCtD
Adenosine—Asthenia—Mitoxantrone—lymphatic system cancer	4.67e-05	0.0023	CcSEcCtD
Adenosine—Dizziness—Carmustine—lymphatic system cancer	4.63e-05	0.00228	CcSEcCtD
Adenosine—Vomiting—Carmustine—lymphatic system cancer	4.45e-05	0.00219	CcSEcCtD
Adenosine—Dizziness—Vincristine—lymphatic system cancer	4.42e-05	0.00218	CcSEcCtD
Adenosine—Rash—Carmustine—lymphatic system cancer	4.41e-05	0.00217	CcSEcCtD
Adenosine—Dermatitis—Carmustine—lymphatic system cancer	4.41e-05	0.00217	CcSEcCtD
Adenosine—Headache—Carmustine—lymphatic system cancer	4.38e-05	0.00216	CcSEcCtD
Adenosine—Tinnitus—Methotrexate—lymphatic system cancer	4.25e-05	0.0021	CcSEcCtD
Adenosine—Vomiting—Vincristine—lymphatic system cancer	4.25e-05	0.00209	CcSEcCtD
Adenosine—Cardiac disorder—Methotrexate—lymphatic system cancer	4.23e-05	0.00209	CcSEcCtD
Adenosine—Rash—Vincristine—lymphatic system cancer	4.21e-05	0.00208	CcSEcCtD
Adenosine—Dermatitis—Vincristine—lymphatic system cancer	4.21e-05	0.00207	CcSEcCtD
Adenosine—Headache—Vincristine—lymphatic system cancer	4.18e-05	0.00206	CcSEcCtD
Adenosine—Nausea—Carmustine—lymphatic system cancer	4.16e-05	0.00205	CcSEcCtD
Adenosine—Vomiting—Mitoxantrone—lymphatic system cancer	4.14e-05	0.00204	CcSEcCtD
Adenosine—Mediastinal disorder—Methotrexate—lymphatic system cancer	4.11e-05	0.00203	CcSEcCtD
Adenosine—Rash—Mitoxantrone—lymphatic system cancer	4.1e-05	0.00202	CcSEcCtD
Adenosine—Dermatitis—Mitoxantrone—lymphatic system cancer	4.1e-05	0.00202	CcSEcCtD
Adenosine—Headache—Mitoxantrone—lymphatic system cancer	4.07e-05	0.00201	CcSEcCtD
Adenosine—Nausea—Vincristine—lymphatic system cancer	3.97e-05	0.00196	CcSEcCtD
Adenosine—Dysgeusia—Methotrexate—lymphatic system cancer	3.89e-05	0.00192	CcSEcCtD
Adenosine—Nausea—Mitoxantrone—lymphatic system cancer	3.86e-05	0.0019	CcSEcCtD
Adenosine—Back pain—Methotrexate—lymphatic system cancer	3.84e-05	0.00189	CcSEcCtD
Adenosine—Vision blurred—Methotrexate—lymphatic system cancer	3.74e-05	0.00184	CcSEcCtD
Adenosine—Cough—Methotrexate—lymphatic system cancer	3.46e-05	0.00171	CcSEcCtD
Adenosine—Convulsion—Methotrexate—lymphatic system cancer	3.44e-05	0.0017	CcSEcCtD
Adenosine—Chest pain—Methotrexate—lymphatic system cancer	3.38e-05	0.00167	CcSEcCtD
Adenosine—Discomfort—Methotrexate—lymphatic system cancer	3.34e-05	0.00165	CcSEcCtD
Adenosine—Anaphylactic shock—Methotrexate—lymphatic system cancer	3.24e-05	0.0016	CcSEcCtD
Adenosine—Hyperhidrosis—Methotrexate—lymphatic system cancer	3.13e-05	0.00154	CcSEcCtD
Adenosine—Hypotension—Methotrexate—lymphatic system cancer	3.03e-05	0.00149	CcSEcCtD
Adenosine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	2.95e-05	0.00146	CcSEcCtD
Adenosine—Paraesthesia—Methotrexate—lymphatic system cancer	2.91e-05	0.00143	CcSEcCtD
Adenosine—Dyspnoea—Methotrexate—lymphatic system cancer	2.89e-05	0.00142	CcSEcCtD
Adenosine—Somnolence—Methotrexate—lymphatic system cancer	2.88e-05	0.00142	CcSEcCtD
Adenosine—Pain—Methotrexate—lymphatic system cancer	2.77e-05	0.00137	CcSEcCtD
Adenosine—Urticaria—Methotrexate—lymphatic system cancer	2.57e-05	0.00127	CcSEcCtD
Adenosine—Hypersensitivity—Methotrexate—lymphatic system cancer	2.39e-05	0.00118	CcSEcCtD
Adenosine—Asthenia—Methotrexate—lymphatic system cancer	2.32e-05	0.00115	CcSEcCtD
Adenosine—Dizziness—Methotrexate—lymphatic system cancer	2.14e-05	0.00106	CcSEcCtD
Adenosine—Vomiting—Methotrexate—lymphatic system cancer	2.06e-05	0.00102	CcSEcCtD
Adenosine—Rash—Methotrexate—lymphatic system cancer	2.04e-05	0.00101	CcSEcCtD
Adenosine—Dermatitis—Methotrexate—lymphatic system cancer	2.04e-05	0.00101	CcSEcCtD
Adenosine—Headache—Methotrexate—lymphatic system cancer	2.03e-05	0.001	CcSEcCtD
Adenosine—Nausea—Methotrexate—lymphatic system cancer	1.92e-05	0.000949	CcSEcCtD
